Grufity logoGrufity logo

ALNY

234.40USD+14.15(+6.42%)Market Closed

Alnylam Pharmaceuticals Inc

Market Summary

USD234.40+14.15Market Closed
6.42%

ALNY Alerts

ALNY Stock Price

RSI Chart

Valuation

Market Cap

25.2B

Price/Earnings

-21.28

Price/Sales

26.18

Price/Cashflow

-44.96

MarketCap/EBT

-21.31

Price/Sales

Profitability

EBT Margin

-122.83%

Return on Equity

1.7K%

Return on Assets

-33.44%

Fundamentals

Revenue

Revenue (TTM)

960.9M

Revenue Y/Y

40.86%

Revenue Q/Q

17.56%

Earnings

Earnings (TTM)

-1.2B

Earnings Y/Y

-98.48%

Earnings Q/Q

-46.33%

Price Action

52 Week Range

117.58236.80
(Low)(High)

Last 7 days

10.2%

Last 30 days

9.4%

Last 90 days

14.1%

Trailing 12 Months

28.2%

Financial Health

Current Ratio

3.48

Debt/Equity

-10.02

Debt/Cashflow

-0.83

Investor Care

Shares Dilution (1Y)

2.87%

Diluted EPS (TTM)

-9.77

Peers (Alternatives to Alnylam Pharmaceuticals)

View All Peers In Detail
NameMkt Capsorted ascendingRevenuePrice %, 1MReturns, 1YP/EP/SRev 1-YrInc 1-Yr
LARGE-CAP
261.0B
57.8B
13.24% 45.49%
20.65
4.55
4.80% 77.95%
224.2B
1.2B
13.13% -41.64%
-111.81
209.81
17.64% -65.25%
81.0B
14.2B
3.50% 20.88%
14.24
5.69
14.88% -8.36%
80.6B
8.7B
3.66% 57.19%
24.61
9.26
22.03% 50.41%
25.2B
960.9M
9.35% 28.19%
-21.28
26.18
28.24% -41.08%
10.6B
1.9B
9.82% 47.16%
16.75
5.91
12.37% 52.98%
10.1B
876.0M
11.31% 51.76%
-19.93
12.09
35.70% -47.34%
MID-CAP
4.1B
-
-3.30% 6.13%
-18.85
63.29
26.15% -23.38%
3.8B
-
48.10% -29.78%
-5.86
917.1
-74.20% -52.72%
3.2B
272.3M
6.14% -50.33%
-4.51
13.74
-18.36% -74.56%
2.9B
334.3M
-1.03% -49.23%
-5.64
8.54
-6.98% -43.97%
SMALL-CAP
1.5B
191.8M
27.64% 144.62%
26.77
8.56
43.59% 60.82%
1.3B
504.0K
12.76% -3.22%
-4.91
2.5K
-66.53% -10.64%
306.1M
66.9M
42.27% -60.18%
-1.4
4.57
-43.57% -69.06%
16.0M
-
3.64% -84.06%
-0.46
19.11
-77.61% 5.14%

Financials for Alnylam Pharmaceuticals

Income Statement (Last 12 Months)
(In Millions)
Description(%) Q/Q2022Q32022Q22022Q12021Q42021Q3
Revenue8.7%961884880844749
  S&GA Expenses14.4%747653628621601
  R&D Expenses6.4%850799776792732
Earnings Before Taxes-20.6%-1,180.27-978.57-892.22-852.14-835.44
Net Income-20.5%-1,182.12-980.72-892.87-852.82-837.90
Balance Sheet
(In Millions)
Description(%) Q/Q2022Q32022Q22022Q12021Q42021Q3
Assets6.2%3,5353,3303,4343,6433,472
  Current Assets8.9%2,6912,4722,5902,8092,675
    Cash Equivalents86.5%1,0735765348201,094
  Inventory29.8%11589798698
  Net PPE1.3%515508504502485
Liabilities14.2%3,6033,1543,0323,0552,716
  Current Liabilities17.5%773658606696611
  Long Term Debt0.1%678677676434-
Shareholder's Equity-138.4%-67.64176401588756
  Retained Earnings-6.8%-6,361.86-5,955.94-5,678.53-5,438.19-5,179.73
  Additional Paid-In Capital0.9%6,1736,1176,0585,969-
Accumulated Depreciation-140----
Shares Outstanding1.7%123121121120119
* denotes actual numbers (not divided by Millions)
Cashflow (Last 12 Months)
(In Millions)
Description(%) Q/Q2022Q32022Q22022Q12021Q42021Q3
Cashflow From Operations3.2%-559.44-578.19-577.23-641.69-614.70
  Share Based Compensation68.8%232138139166155
Cashflow From Investing79.4%-104.14-506.30-492.07-273.3042
Cashflow From Financing-29.7%6559311,2311,2471,173

Risks

What is the probability of a big loss on ALNY?

94.6%


Probability that Alnylam Pharmaceuticals stock will be more than 20% underwater in next one year

46.9%


Probability that Alnylam Pharmaceuticals stock will be more than 30% underwater in next one year.

18.5%


Probability that Alnylam Pharmaceuticals stock will be more than 40% underwater in next one year.
*Calculated based on probability distribution of losses observed in actual data in the last 5 years.

How does ALNY drawdown profile look like?

Y-axis is the maximum loss one would have experienced if Alnylam Pharmaceuticals was unfortunately bought at previous high price.

Returns

Cumulative Returns on ALNY

30.5%


10-Year Cumulative Returns

11.6%


7-Year Cumulative Returns

11.3%


5-Year Cumulative Returns

24.2%


3-Year Cumulative Returns

What are the long-term rolling returns for ALNY?

FIve years rolling returns for Alnylam Pharmaceuticals.

Which funds bought or sold ALNY recently?

View All Details
Datesorted ascendingFund NameType% Chg$ Change$ Held% Portfolio
2022-11-29
Bridgefront Capital, LLC
NEW
-
385,000
385,000
0.40%
2022-11-23
Toroso Investments, LLC
ADDED
35.01
225,000
489,000
0.02%
2022-11-22
CVA Family Office, LLC
REDUCED
-50
-
1,000
-%
2022-11-22
TEACHERS RETIREMENT SYSTEM OF THE STATE OF KENTUCKY
NEW
-
11,900,000
11,900,000
0.14%
2022-11-21
CALIFORNIA STATE TEACHERS RETIREMENT SYSTEM
REDUCED
-0.81
10,536,000
39,702,000
0.07%
2022-11-21
Parallax Volatility Advisers, L.P.
SOLD OFF
-100
-1,864,000
-
-%
2022-11-18
National Pension Service
REDUCED
-13.22
6,488,000
32,872,000
0.07%
2022-11-18
Industrial Alliance Investment Management Inc.
REDUCED
-58.86
-1,065,000
1,381,000
0.04%
2022-11-17
CENTRAL TRUST Co
UNCHANGED
-
3,000
13,000
-%
2022-11-17
M&T Bank Corp
ADDED
45.98
665,000
1,327,000
0.01%

1–10 of 43

Latest Funds Activity

Are funds buying ALNY calls or puts?
Are funds bullish or bearish(Calls - Puts)?
No. of funds that own ALNY

Alnylam Pharmaceuticals News

MarketWatch

Incyte Corp. stock rises Friday, outperforms market.33 hours ago

ALNY Fair Value

Recent SEC filings of Alnylam Pharmaceuticals

View All Filings
Date Filed Form Type Document
Nov 23, 2022
4
Insider Trading
Oct 27, 2022
8-K
Current Report
Oct 27, 2022
10-Q
Quarterly Report
Sep 16, 2022
8-K
Current Report
Sep 13, 2022
8-K
Current Report
Sep 09, 2022
SC 13G
Major Ownership Report
Aug 24, 2022
8-K
Current Report
Aug 24, 2022
4
Insider Trading
Aug 24, 2022
3
Insider Trading

Latest Insider Trading transactions for ALNY

Filter Transactions
Datesorted ascendingNameBuy/Sell$ ValueAvg. Price# SharesTitle
2022-11-21
Ausiello Dennis A
SOLD
-4,950,000
220
-22,500
-
2022-11-21
Ausiello Dennis A
ACQUIRED
1,599,640
71.095
22,500
-
2022-08-15
SHARP PHILLIP A
ACQUIRED
1,137,070
33.7709
33,670
-
2022-08-15
SHARP PHILLIP A
SOLD
-7,760,740
230.494
-33,670
-
2022-08-05
Tanguler Tolga
SOLD
-401,630
218.159
-1,841
EVP, Chief Commercial Officer
2022-08-04
Tanguler Tolga
SOLD (Taxes)
-342,817
191.732
-1,788
EVP, Chief Commercial Officer
2022-08-04
Garg Pushkal
SOLD (Taxes)
-974,201
191.546
-5,086
CMO & EVP Dev & Med Affairs
2022-08-04
Vaishnaw Akshay
SOLD (Taxes)
-1,160,340
191.728
-6,052
President
2022-08-04
Poulton Jeffrey V.
SOLD (Taxes)
-968,824
191.694
-5,054
EVP, Chief Financial Officer
2022-08-04
Greenstreet Yvonne
SOLD (Taxes)
-1,150,440
191.676
-6,002
Chief Executive Officer

1–10 of 50

Yvonne L. Greenstreet
1660
Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. The company's pipeline of investigational RNAi therapeutics focuses on genetic medicines, cardio-metabolic diseases, hepatic infectious diseases, and central nervous system (CNS)/ocular diseases. Its marketed products include ONPATTRO (patisiran), a lipid complex injection for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria (AHP); and OXLUMO (lumasiran) for the treatment of primary hyperoxaluria type 1 (PH1). In addition, the company is developing givosiran for the treatment of adolescent patients with AHP; patisiran for the treatment of transthyretin amyloidosis, or ATTR amyloidosis, with cardiomyopathy; cemdisiran to treat complement-mediated diseases; ALN-AAT02 for the treatment of AAT deficiency-associated liver disease; ALN-HBV02 to treat chronic HBV infection; Zilebesiran to treat hypertension; and ALN-HSD to treat NASH. Further, it offers Fitusiran for the treatment of hemophilia and rare bleeding disorders, Inclisiran to treat hypercholesterolemia, lumasiran for the treatment of advanced PH1 and recurrent renal stones, and vutrisiran for the treatment of ATTR amyloidosis, which is in phase 3 clinical trial. Alnylam Pharmaceuticals, Inc. has strategic collaborations with Regeneron Pharmaceuticals, Inc. to discover, develop, and commercialize RNAi therapeutics for a range of diseases by addressing therapeutic targets expressed in the eye and CNS; and Sanofi Genzyme to discover, develop, and commercialize RNAi therapeutics. It also has license and collaboration agreements with Novartis AG; Vir Biotechnology, Inc.; Dicerna Pharmaceuticals, Inc.; Ionis Pharmaceuticals, Inc.; and PeptiDream, Inc. The company was founded in 2002 and is headquartered in Cambridge, Massachusetts.

ALNY Income Statement

2022-09-30
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS - USD ($)
shares in Thousands, $ in Thousands
3 Months Ended9 Months Ended
Sep. 30, 2022
Sep. 30, 2021
Sep. 30, 2022
Sep. 30, 2021
Revenues:    
Total revenues$ 264,306$ 187,633$ 702,383$ 585,752
Operating costs and expenses:    
Cost of goods sold36,50728,09194,00281,370
Cost of collaborations and royalties4,6094,57223,54921,110
Research and development245,371194,572620,976563,106
Selling, general and administrative235,859142,075560,314434,257
Total operating costs and expenses522,346369,3101,298,8411,099,843
Loss from operations(258,040)(181,677)(596,458)(514,091)
Other (expense) income:    
Interest expense(41,084)(40,274)(126,055)(106,205)
Other (expense) income, net(30,233)17,715(120,873)28,454
Loss on extinguishment of debt(76,586)0(76,586)0
Total other expense, net(147,903)(22,559)(323,514)(77,751)
Loss before income taxes(405,943)(204,236)(919,972)(591,842)
Benefit from (provision for) income taxes23(278)(3,691)(2,522)
Net loss$ (405,920)$ (204,514)$ (923,663)$ (594,364)
Net loss per common share - basic (in dollars per share)$ (3.32)$ (1.72)$ (7.62)$ (5.04)
Net loss per common share - diluted (in dollars per share)$ (3.32)$ (1.72)$ (7.62)$ (5.04)
Weighted-average common shares used to compute basic net loss per common share (in shares)122,166119,141121,158118,005
Weighted-average common shares used to compute diluted net loss per common share (in shares)122,166119,141121,158118,005
Statements of Comprehensive Loss    
Net loss$ (405,920)$ (204,514)$ (923,663)$ (594,364)
Other comprehensive (loss) income:    
Unrealized loss on marketable securities(2,053)(64)(11,004)(312)
Foreign currency translation gain4601,8573779,530
Defined benefit pension plans, net of tax3458103174
Total other comprehensive (loss) income(1,559)1,851(10,524)9,392
Comprehensive loss(407,479)(202,663)(934,187)(584,972)
Net revenues from collaborations    
Revenues:    
Total revenues29,29720,13664,267121,328
Net product revenues    
Revenues:    
Revenues232,267167,044632,654463,624
Royalty revenue    
Revenues:    
Revenues$ 2,742$ 453$ 5,462$ 800

ALNY Balance Sheet

2022-09-30
CONDENSED CONSOLIDATED BALANCE SHEETS - USD ($)
$ in Thousands
Sep. 30, 2022
Dec. 31, 2021
Current assets:  
Cash and cash equivalents$ 1,073,228$ 819,975
Marketable debt securities1,169,0501,548,617
Marketable equity securities23,05166,972
Accounts receivable, net184,513198,571
Inventory115,48986,363
Prepaid expenses and other current assets125,51688,078
Total current assets2,690,8472,808,576
Property, plant and equipment, net514,821501,958
Operating lease right-of-use assets218,802231,675
Restricted investments49,38940,891
Other assets61,39660,204
Total assets3,535,2553,643,304
Current liabilities:  
Accounts payable40,57273,426
Accrued expenses510,579395,174
Operating lease liability41,58140,548
Deferred revenue144,208149,483
Liability related to the sale of future royalties35,85137,079
Total current liabilities772,791695,710
Operating lease liability, net of current portion266,323281,347
Deferred revenue, net of current portion132,930152,360
Convertible debt1,015,9750
Long-term debt0675,697
Liability related to the sale of future royalties, net of current portion1,231,8731,151,024
Other liabilities183,00198,963
Total liabilities3,602,8933,055,101
Commitments and contingencies (Note 14)
Stockholders’ (deficit) equity:  
Preferred stock, $0.01 par value per share, 5,000 shares authorized and no shares issued and outstanding as of September 30, 2022 and December 31, 202100
Common stock, $0.01 par value per share, 250,000 shares authorized; 122,991 shares issued and outstanding as of September 30, 2022; 120,182 shares issued and outstanding as of December 31, 20211,2301,202
Additional paid-in capital6,336,7716,058,453
Accumulated other comprehensive loss(43,783)(33,259)
Accumulated deficit(6,361,856)(5,438,193)
Total stockholders’ (deficit) equity(67,638)588,203
Total liabilities and stockholders’ (deficit) equity$ 3,535,255$ 3,643,304